Medical Device | December 10, 2021
Indian government approves eight firms for PLI scheme
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
Officials from ACG signed the MoU with the Maharashtra government for the Rs 600 crore investment in the backward region of Marathwada
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
